Open Access
How to translate text using browser tools
1 October 2004 GnRH as a Cell Proliferation Regulator: Mechanism of Action and Evolutionary Implications
Masahiro Enomoto, Min Kyun Park
Author Affiliations +
Abstract

Gonadotropin-releasing hormone (GnRH) is well known as the central regulator of the reproductive system through its stimulation of gonadotropin release from the pituitary. Studies on GnRH have demonstrated that GnRH has both stimulatory and inhibitory effects on cell proliferation depending on the cell type; however, the mechanisms of these effects remain to be elucidated. Against this background we used four human cell lines, TSU-Pr1, Jurkat, HHUA and DU145, and newly found that GnRH increased or decreased the colony-formation depending on the cell line. Moreover, we demonstrated that the stimulatory and inhibitory effects of GnRH exhibit distinct ligand selectivities. In order to investigate the molecular basis of these phenomena, analyses of the expression of human GnRH receptors were performed and, moreover, the effects of GnRH were analyzed under conditions in which human GnRH receptors were knocked down by the technique of RNA interference. Consequently, it was found that human type II GnRH receptor, which had been suspected of being nonfunctional because of alterations in its sequence, is involved in the effects of GnRH on cell proliferation. In this article, the influence of the autocrine activities of the cells is also reviewed, focusing on the characteristics of substances secreted from the four cell lines. Based on recent studies of GnRH and its receptors and our up-to-date findings, the evolutionary implications of GnRH action are discussed.

INTRODUCTION

GnRH was originally identified as a hypothalamic decapeptide which promotes gonadotropin secretion from pituitary gonadotropes and was named gonadotropin-releasing hormone (Matsuo et al., 1971; Amoss et al., 1971). Thereafter, multiple GnRH isoforms and multiple types of GnRH receptors were reported in a wide range of organisms in addition to vertebrates (Millar et al., 2004) and broad distribution of them in extrapituitary tissues and organs has been demonstrated (Klausen et al., 2002; Millar, 2003; Ikemoto et al., 2003, 2004). Through these observations the study of extrapituitary GnRH systems has become one of the important topics regarding the physiological significance of GnRH. The concept of extrapituitary GnRH systems is also important in terms of the evolution of the reproductive system. Now that the existence of GnRH has been confirmed in invertebrates, which have no pituitary gland, it is suggested that in these organisms GnRH acts directly on the gonads (Terakado, 2001; Kusakabe et al., 2003). In our previous studies (Kogo et al., 1995, 1999a, b; Park et al., 1999), GnRH receptor mRNA expression was demonstrated in the rat ovary, which strongly suggests the idea that GnRH is involved in the induction of follicular atresia and ovulation (Table 1). There have also been other studies suggesting that GnRH directly controls gonadal function. (Gobetti et al., 1992; Fasano et al., 1995; Takekida et al., 2003; Sifer et al., 2003), however clear evidence supporting this suggestion has not been obtained yet. Moreover, in addition to the direct effects on gonads, it has been reported that GnRH may act as a neuromodulator or an immunomodulator. (Eisthen et al., 2000; Oka, 2002; Ford et al., 2003; Azad et al., 1997; Enomoto et al., 2001; Chen et al., 2002). Although a number of studies have been performed on these effects of GnRH, little is known about the molecular mechanisms and physiological settings in which GnRH exerts its activities in extrapituitary tissues or organs.

Table 1

GnRH receptor mRNA expression on the rat ovary.

i0289-0003-21-10-1005-t01.gif

There are interesting in vitro studies about the diverse functions of GnRH. GnRH promotes or inhibits cell proliferation depending on the cell type. As for the promotive effects of GnRH, effects on thymocytes, splenocytes, and lymphocytes have been reported (Marchetti et al., 1989; Batticane et al., 1991; Azad et al., 1997). Regarding inhibitory effects, effects against hormone-related tumors are well known, and these effects are now applied clinically (Schally, 1999; Grundker et al., 2002). These opposite effects of GnRH on cell proliferation are very interesting, but it has remained unknown whether GnRH has such activities in physiological settings, mainly because most previous studies were performed using cancer cell lines and pharmacological doses of GnRH. However, recently, the effects of GnRH on the cell proliferation of non-tumor cells, as well as on cell adhesion, cell migration, and cytoskeletal remodeling have been reported (Chen et al., 2002; Romanelli et al., 2004; Davidson et al., 2004) and the physiological roles of the effects of GnRH on cell proliferation are being reconsidered.

In fact, there is evidence for the effects of GnRH on gonadotrope cell proliferation (Sakai et al., 1988; Kakar et al., 1997; Miles et al., 2004), and thus GnRH may originally act as one of the cell growth regulators of gonadotropes. Moreover, there is a possibility that the activities of GnRH that alter their direction of effects depending on the cell type underlie the diverse physiological functions of GnRH. We have focused on the two opposite effects of GnRH on cell proliferation, particularly the relationship between these effects and the diverse functions of GnRH, and investigated the molecular mechanisms of the effects of GnRH on cell proliferation. So far, we have found stimulatory and inhibitory activities of the physiological dose of GnRH on the colony-formation of cells using an originally established method, the colony-forming efficiency assay (Enomoto et al., 2001 and 2004a, b). The experimental models used in our studies are TSU-Pr1 (from human prostatic carcinoma, Iizumi et al., 1987), Jurkat (from human mature leukemia, Gills and Watson, 1980), DU145 (from human prostatic carcinoma, Mickey et al., 1977; Stone et al., 1978), and HHUA (from human endometrial carcinoma, Ishiwata et al., 1984) cell lines. Recently, interesting findings about the mechanisms of the two opposite effects of GnRH have been obtained by adaptation of the technique of RNA interference to our original assay system (Enomoto et al., 2004b). Moreover, we have obtained strong evidence for the influence of autocrine activities of the cells on the GnRH effects (Enomoto et al., 2001, 2004a). In this article, our up-to-date findings about the mechanisms of the stimulatory and inhibitory effects of GnRH will be reviewed, focusing on human GnRH receptors and the influence of autocrine activities of the cells on the GnRH effects. The evolutionary implication of the GnRH activities on cell proliferation will be also discussed.

1. Effects of GnRH on colony-formation

1-1. Stimulatory and inhibitory effects of GnRH

A number of studies have demonstrated that various carcinomas of breast, ovary, endometrium, prostate, pancreas and liver origin respond to GnRH and its analogues (Schally, 1999). It has also been reported that treatment of thymocytes, splenocytes, and lymphocytes with GnRH and its analogues increased their proliferative activity (Marchetti et al., 1989; Batticane et al., 1991; Azad et al., 1997). In these studies the effects of GnRH on cell proliferation were investigated by measuring tumor weight and/or volume, the rate of cell proliferation, or 3H-thymidine incorporation (Redding and Schally, 1983; Sharoni et al., 1989; Pati and Habibi, 1995; Dondi et al., 1998). However, to our knowledge, there have been no studies that compared stimulatory with inhibitory effects. One of the reasons for this was the lack of a method that makes it possible to detect both effects sensitively. Thus, we first established an original assay, the colony-forming efficiency assay (Enomoto et al., 2001). The colony-forming efficiency assay is based on limiting dilution analysis with minor modifications. The detailed procedure was described in our previous report (Enomoto et al., 2001).

Fig. 1 shows the effects of GnRH-I on the colony-forming efficiency. The slope of the linearly regressed line represents the colony-forming efficiency. In TSU-Pr1 and Jurkat cells, GnRH-I increased the colony-forming efficiency, whereas, in DU145 and HHUA cells, the colony-forming efficiency was decreased by GnRH-I. We also examined the effects of GnRH-I on the rate of cell proliferation and confirmed that the response to GnRH of each cell line was the same as that on colony-forming efficiency. This fact suggests that the colony-forming efficiency assay is useful for studying the effects of GnRH on cell proliferation. Moreover, it is very interesting that TSU-Pr1 and DU145, which are derived from human prostatic carcinoma, exhibited the opposite responses to GnRH stimulation.

Figure 1

Effects of GnRH-I (final concentration, 100 pM) on the colony-forming efficiency of TSU-Pr1 (a), Jurkat (b), DU145 (c), and HHUA (d) cells (**p<0.01). The number of cells plated per well was 1, 2, 4, and 8 cells in the cases of TSU-Pr1, DU145, and HHUA cells and 5, 10, 20, and 40 cells in the case of Jurkat cells.

i0289-0003-21-10-1005-f01.gif

1-2. Distinct ligand selectivities of the stimulatory and inhibitory effects

As described above, we succeeded in detecting the stimulatory and inhibitory effects of GnRH on the colony-forming efficiency. To clarify the characteristics of these effects, ligand selectivities were investigated using the four cell lines. As GnRH ligands, we used GnRH-I and II and Cetrorelix (synthetic type I GnRH receptor antagonist) (Reissmann et al., 2000). Humans GnRHs consist of GnRHI and II (Matsuo et al., 1971; Amoss et al., 1971; Miyamoto et al., 1984). The results revealed that the stimulatory and inhibitory effects exhibited distinct patterns (Fig. 2). Fig. 2a and 2b show representative results. In Jurkat cells, the pattern is similar to that of TSU-Pr1 cells, and in HHUA the pattern is similar to that of DU145 (data not shown). In positively responding cell lines (TSU-Pr1 and Jurkat) GnRH-I was more effective (about 10 fold) than GnRH-II, and Cetrorelix had no effect. On the other hand, in negatively responding cell lines (DU145 and HHUA) GnRH-II was much more effective (1,000 to 10,000 fold) than GnRH-I. Interestingly, Cetrorelix behaved as an agonist. Fig. 2c lists the EC50 values of all nonlinearly fitted curves. Based on the classical ligand-receptor theory, this result strongly suggests that the stimulatory and inhibitory effects of GnRH are mediated by different GnRH receptors. Thus, we investigated this possibility as described in the following chapter.

Figure 2

Ligand selectivities for colony-formation of TSU-Pr1 (a) and DU145 (b) cells. The cell densities were 8 cells per well. The abscissa and ordinate represent the concentration of GnRH ligand and the fraction of colony-containing wells (the number of colony-containing wells per total wells), respectively. Results are expressed as means±SE (n=4). c. EC50 values of all nonlinearly fitted curves in TSU-Pr1, Jurkat, DU145, and HHUA cells.

i0289-0003-21-10-1005-f02.gif

2. Two types of human GnRH receptors

2-1. Expression of human GnRH receptors

Among the human GnRH receptors, type I (hGnRHR-1) and II (hGnRHR-2) GnRH receptors are known. Type I receptor was cloned first and has been well characterized (Kakar et al., 1992), and recently the genomic loci encoding the human type II GnRH receptor has been cloned (Faurholm et al., 2001). However, previous studies revealed a puzzling fact about the human type II GnRH receptor gene. The protein coding sequences contain a frameshift mutation and a TGA stop codon, compared with other primate type II GnRH receptor sequences that were demonstrated to be functional (Faurholm et al., 2001; Neill, 2002; Morgan et al., 2003). So far, no full-length sequence of a human type II receptor that is translated into protein has been discovered.

In 2001, Millar et al. demonstrated that human type I GnRH receptor and marmoset type II GnRH receptor, which has 90% amino acid identity with the deduced human type II GnRH receptor amino acid sequence, exhibited distinctly different patterns of ligand selectivity, as shown Fig. 2. This result strongly suggests that human type II GnRH receptor is functional as a receptor, and we first presumed that the distinctly different patterns of ligand selectivity between the stimulatory and inhibitory effects should be due to the expression of a different GnRH receptor subtype. Thus we performed expression analyses of human GnRH receptors in the four cell lines. For hGnRHR-1, a single PCR product was amplified with one primer set in all four cell lines (upper panel in Fig. 3). In contrast, for hGnRHR-2, two PCR products were amplified with one primer set in all four cell lines (lower panel in Fig. 3). The results of direct sequencing demonstrated that the longer PCR product was identical with the human type II GnRH receptor (GeneBank accession No.  AY077708) (Van Biljon et al., 2002), and the lower one was identical with the human type II GnRH receptor splice variant (hGnRHR-2v) (GeneBank accession No.  AY081843) (Neill, 2002). As shown in Fig. 3, all four cell lines expressed hGnRHR-1, 2, and 2v, which suggests that the opposite responses to GnRH stimulation may not be due to the differences of expressed GnRH receptor subtypes.

Figure 3

Expression of human GnRH receptor 1 (the upper panel), 2 and 2 variant (the lower panel) in TSU-Pr1, Jurkat, DU145, and HHUA cells. RT- are negative controls in which non-reverse transcribed mRNA of each cell line was used as the template. The left-hand lane contains the molecular marker.

i0289-0003-21-10-1005-f03.gif

2-2. Involvement of each human GnRH receptor in the effects of GnRH

In the expression analyses, no clear differences between positively responding cell lines (TSU-Pr1 and Jurkat) and negatively responding cell line (DU145 and HHUA) were observed. Next we examined the effects of GnRH-I and II and Cetrorelix on colony-forming efficiency under the condition that the expression of each of the human GnRH receptors was suppressed individually by the technique of RNA interference (RNAi) using pSilencer 2.0-U6, a short hairpin interfering RNA (shRNA) expression vector (Ambion Inc., Austin, TX). This technique efficiently induces sequence-specific mRNA degradation and thereby suppresses the target gene expression (Brummelkamp et al., 2002; Hannon, 2002; Shi, 2003; Dykxhoor et al., 2003), and thus the roles of human type II GnRH receptor and its splice variant can be investigated even if they don't function as proteins. Table 2 shows the summary of the complete results. As a negative control, we used the pSilencer negative control vector encoding a shRNA whose sequence is not found in the mouse, rat, or human genome databases (Ambion Inc., Austin, TX), and the resultant colony-forming efficiencies were the same as those of non-transfected cells (data not shown).

Table 2

Summary of the results when each human GnRH receptor was knocked down.

i0289-0003-21-10-1005-t02.gif

As shown in Table 2, when hGnRHR-1 was knocked-down, all three GnRH ligands failed to show significant effects and the colony-forming efficiencies were similar to those of the non-transfected cells. When hGnRHR-2 was knocked-down, GnRH-II and Cetrorelix had no significant effects, and only GnRH-I was significantly effective. For hGnRHR-2v, quite interesting and remarkable results were obtained. When hGnRHR-2v was knocked-down, the direction of response to the stimulation of GnRH-I and II in TSU-Pr1 and Jurkat cells was reversed from a positive effect to a negative one, and Cetrorelix behaved as an agonist. To the best of our knowledge, this result is the first demonstration that a receptor can regulate the direction of the response to the ligand stimulation. As for DU145 and HHUA cells, no such alteration was observed upon the suppression of hGnRHR-2v. Although hGnRHR-2v mRNA is expressed in DU145 and HHUA cells, it appears to have no function in these cells. This fact may be due to the balance of the expression levels of hGnRHR-2 and 2v. In fact, as shown in Fig. 3, in DU145 and HHUA cells these levels are quite different, whereas in Jurkat and TSU-Pr1 cells they are much less different; however, further studies will be necessary to clarify this point.

Summarizing our results focusing on each receptor, hGnRHR-1 was indispensable for the effectiveness of all three GnRH ligands, and hGnRHR-2 was necessary for the effectiveness of GnRH-II and Cetrorelix. Furthermore, hGnRHR-2v plays a role in mediating the stimulatory effects of GnRH-I and II and the effectiveness of Cetrorelix. One possible explanation for these complicated results is that hGnRHR-2 and 2v directly interact with hGnRHR-1 and form hetero-dimers or oligomers. In fact, many recent studies have provided evidence that G-protein coupled receptors (GPCRs) can exist as either dimers or higher order oligomers (Milligan et al., 2004; Pfleger et al., 2004). Promotion or inhibition of signal transduction by ligand stimulation and alteration of G-protein selectivity by receptor dimerization have been also reported (AbdAlla et al., 2001a, b). Moreover, there is evidence that co-expression of GPCR pairs can generate distinct ligand-binding sites (Maggio et al., 1998). Fig. 4 shows one of the proposed structural models for GPCR receptor dimers, 5,6-domain swapped dimers (Gouldson et al., 1998). Each transmembrane alpha helix is represented as a circle. The hinge loop represents intracellular loop 3. As shown in this figure, another binding pocket is generated by receptor dimerization. This could account for our distinct patterns of ligand selectivities. We should also consider the possibility of cross-talk among intracellular signalings and functions as non-coding RNAs (Storz, 2002) of hGnRHR-2 and 2v mRNAs to modulate the signaling mediated by hGnRHR-1. However, in any case, further investigations of the human type II GnRH receptor and the splice variant will be required to elucidate the detailed mechanisms by which human type II GnRH receptor and its splice variant are involved in the effects of GnRH on cell proliferation.

Figure 4

Schematic models of the monomer and the 5,6-domain swapped dimer of G-protein coupled receptor. Each transmembrane alpha helix is represented as a circle. The hinge loop represents intracellular loop 3. The presumed binding pockets are shown as grey areas.

i0289-0003-21-10-1005-f04.gif

3. Influence of autocrine activities of the cells on the GnRH effects

The colony-forming efficiency assay is a method that can examine cell proliferation at the low cell density (10 to 400 cells per ml). In our previous study, the effects of GnRH on the rate of cell proliferation at high cell density (20,000 cells per ml) were also investigated and interesting facts about the effects of GnRH were found. The assay was done as follows. At first, Jurkat and HHUA cells were inoculated in flat-bottomed 24-well plates (20,000 cells per ml). The day when cells were inoculated was defined as Day 0. Buserelin, a synthetic GnRH agonist was added (final concentration, 5 pg/ml) only after 24 hours or every 24 hours. In results, Buserelin had no significant effect on the rate of cell proliferation of either Jurkat or HHUA cells (data not shown). However, as shown in Fig. 5c, when Buserelin was added with daily exchange of the culture medium, the rate of cell proliferation was significantly increased or decreased in Jurkat or HHUA cells, respectively (Fig. 5a and 5b). From these results we presumed that the accumulation of substances secreted from the cells into the medium influenced the effects of GnRH on cell proliferation. To confirm this possibility, we measured the colony-forming efficiency in the presence of conditioned media of Jurkat, HHUA and TSU-Pr1 cells. Conditioned medium is the medium in which cells have been cultured for several days, and thus it contains substances secreted from cells during the culture period. The experimental groups prepared are shown in Fig. 6a. The detailed procedure of this experiment was described in our previous report (Enomoto et al., 2001).

Figure 5

Effects of Buserelin (final concentration, 5 pg/ml) on the rate of cell proliferation of Jurkat (a) and HHUA (b) cells when culture medium was exchanged every 24 hours. Results are expressed as means±SE (n=4; **p<0.01; ***p<0.001). The experimental schedule is illustrated in c.

i0289-0003-21-10-1005-f05.gif

Figure 6

Summary of the effects of conditioned media derived from Jurkat, HHUA and TSU-Pr1 cells on the colony-forming efficiencies. a. Experimental groups. b. Three patterns of the influence of conditioned media. c. Summarized results of the effects of each conditioned medium on the colony-forming efficiencies of Jurkat, HHUA, and TSU-Pr1 cells.

i0289-0003-21-10-1005-f06.gif

As shown in Fig. 6b, the colony-forming efficiencies in the presence of conditioned media of Jurkat, HHUA and TSU-Pr1 cells were classified into three patterns. In the case of Pattern 1, in the presence of the conditioned medium, the colony-forming efficiency (Group 3 and 4) was nearly equal to that of Group 2, being independent of the addition of GnRH. In contrast, in the case of Pattern 2, the colony-forming efficiency in the presence of conditioned medium (Group 3 and 4) was nearly equal to that of Group 1, being independent of the addition of GnRH. In Pattern 3, the presence of the conditioned medium had no effect. Fig. 6c shows the comprehensive results based on the classification of the three patterns. These results indicate that the conditioned medium of Jurkat cells mimicked the GnRH activity, whereas that of HHUA cells inhibited it. In other words, Jurkat cells secrete a GnRH-like substance and HHUA cells secrete a GnRH-inhibiting substance in terms of the effects on cell proliferation. However, the conditioned medium of TSU-Pr1 cells inhibited the GnRH activity only in TSU-Pr1 cells themselves. In HHUA cells, it had no effect, whereas in Jurkat cells, it severely decreased the colony-forming efficiency and statistically analyzable data could not be obtained. Summarizing these results, the conditioned media of Jurkat and HHUA cells consistently affected the GnRH activities regardless of the cell type, whereas that of TSUPr1 had cell type-dependent effects. Our results suggest that each of these three cell lines secrete a distinct substance that affects GnRH activities, and these substances will be identified in future studies.

Our interpretation of the results introduced in this chapter is schematized in Fig. 7. At low cell density, GnRH promotes or suppresses cell proliferation depending on the cell type. In contrast, at high cell density autocrine factors of the cells mimic or inhibit the GnRH activity and the effects of GnRH are masked. From this point of view, the colony-forming efficiency assay is a sensitive method that can limit the effects of autocrine activity of the cells.

Figure 7

Cartoon illustrating the response of cells simulated by GnRH at low and high cell density.

i0289-0003-21-10-1005-f07.gif

EVOLUTIONARY IMPLICATIONS

In this article, we reviewed our recent findings about the mechanisms of the stimulatory and inhibitory effects of GnRH on cell proliferation, focusing on the involvement of GnRH receptors. The detailed role of each receptor remains to be elucidated. In addition, we described the autocrine activities of the cells that affect the GnRH effects. Identification of these factors is important to clarify the effects of GnRH on cell proliferation in vivo.

Viewing the historical progress on studies of GnRH, we are reminded of one of the bioactive substances in the hypothalamus-pituitary-gonadal axis, namely activin. Activin was originally isolated based on its activity in stimulating follicle-stimulating hormone (FSH) release from the anterior pituitary (Ling et al., 1986; Vale et al., 1986). In addition to its endocrine function, activin has been found to possess various activities in different biological systems, e.g., erythroid differentiation, nerve cell survival, Xenopus laevis embryonic mesoderm induction, bone growth promotion, and somatostatin induction (Mathews, 1994). Subsequently, it was found that activin regulates a wide variety of cellular events, including cell proliferation, differentiation, and apoptosis. For example, in addition to endocrine function in the pituitary, activin also controls the activity of the hypothalamus and ovary, indicating that activin has profound autocrine and paracrine effects on the female reproductive system (Peng and Mukai, 2000). GnRH was originally identified as a hypothalamic decapeptide that promotes gonadotropin release, and thereafter a number of studies have strongly suggested that it has various physiological activities, such as neuro-modulation, immunomodulation, and regulation of follicular atresia and ovulation. Moreover, it was demonstrated that GnRH regulates cell proliferation, cell migration, and cell attachment. Based on these similarities between activin and GnRH, the idea that GnRH may have roles in embryogenesis and morphogenesis occurs to us. In fact, there have been several reports suggesting that GnRH may play a substantial autocrine or paracrine role in human fertilization, early embryonic development, and implantation (Seshagiri et al., 1994; Casan et al., 1999; Raga et al., 1999). From these points of view, our studies of the molecular mechanisms of the GnRH actions on cell proliferation will provide important clues for clarifying the physiological roles of GnRH, particularly in embryogenesis and morphogenesis. Moreover, extending our findings about human GnRH receptor signalings to other species will lead to a comprehensive understanding of the GnRH system, including the GnRH system in invertebrates, and clarification of the evolution of the reproductive system.

Acknowledgments

We heartily express great gratitude to S. Kawashima (Emeritus Professor, The University of Tokyo) for helpful advice throughout our study. We are also grateful to Prof. T. Minegishi (Department of Obstetrics and Gynaecology, School of Medicine, Gunma University) for a gift of Cetrorelix and Dr. T. Iizumi (Department of Urology, Teikyo University School of Medicine) and Dr. J. Y. Seong and Ms. D. Y. Oh (Hormone Research Center, Chonnam National University) for helpful advice on culturing TSU-Pr1 cells. Lastly, we are thankful to Prof. Y. Oka, Dr. Y. Akazome and Ms. M. Kyokuwa (Department of Biological Sciences, Graduate School of Science, The University of Tokyo) for supports throughout our study. Our studies summarized in this review were supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES

1.

S. AbdAlla, H. Lother, A. el Massiery, and U. Quitterer . 2001. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003–1009. Google Scholar

2.

S. AbdAlla, H. Lother, A. M. Abdel-tawab, and U. Quitterer . 2001. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276:39721–39726. Google Scholar

3.

M. Amoss, R. Burgus, R. Blackwell, W. Vale, R. Fellows, and R. Guillemin . 1971. Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochem Biophys Res Commun 44:205–210. Google Scholar

4.

N. Azad, N. LaPaglia, L. Kirsteins, S. Uddin, J. Steiner, D. W. Williams, A. M. Lawrence, and N. V. Emanuele . 1997. Jurkat cell proliferative activity is increased by luteinizing hormone-releasing hormone. J Endocrinol 153:241–249. Google Scholar

5.

N. Batticane, M. C. Morale, F. Gallo, Z. Farinella, and B. Marchetti . 1991. Luteinizing hormone-releasing hormone signaling at the lymphocyte involves stimulation of interleukin-2 receptor expression. Endocrinology 129:277–286. Google Scholar

6.

T. R. Brummelkamp, R. Bernards, and R. Agami . 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553. Google Scholar

7.

E. M. Casan, F. Raga, and M. L. Polan . 1999. GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod 5:234–239. Google Scholar

8.

A. Chen, Y. Ganor, S. Rahimipour, N. Ben-Aroya, Y. Koch, and M. Levite . 2002. The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8:1421–1426. Google Scholar

9.

L. Davidson, A. J. Pawson, R. P. Millar, and S. Maudsley . 2004. Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. J Biol Chem 279:1980–1993. Google Scholar

10.

D. Dondi, R. M. Moretti, M. Montagnani Marelli, G. Pratesi, D. Polizzi, M. Milani, M. Motta, and P. Limonta . 1998. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 76:506–511. Google Scholar

11.

D. M. Dykxhoorn, C. D. Novina, and P. A. Sharp . 2003. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467. Google Scholar

12.

H. L. Eisthen, R. J. Delay, C. R. Wirsig-Wiechmann, and V. E. Dionne . 2000. Neuromodulatory effects of gonadotropin releasing hormone on olfactory receptor neurons. J Neurosci 20:3947–3955. Google Scholar

13.

M. Enomoto, T. Mori, and M. K. Park . 2001. GnRH agonist Buserelin affects colony-forming efficiency of HHUA and Jurkat cells. Biochem Biophys Res Commun 289:1180–1187. Google Scholar

14.

M. Enomoto, J. Y. Seong, S. Kawashima, and M. K. Park . 2004. Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone. Life Sci 74:3141–3152. Google Scholar

15.

M. Enomoto, D. Endo, S. Kawashima, and M. K. Park . 2004. Human type II GnRH receptor mediates effects of GnRH on cell proliferation. Zool Sci 21:763–770. Google Scholar

16.

S. Fasano, M. D'Antonio, P. Chieffi, G. Cobellis, and R. Pierantoni . 1995. Chicken GnRH-II and salmon GnRH effects on plasma and testicular androgen concentrations in the male frog, Rana esculenta, during the annual reproductive cycle. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112:79–86. Google Scholar

17.

B. Faurholm, R. P. Millar, and A. A. Katz . 2001. The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci. Genomics 78:15–18. Google Scholar

18.

C. P. Ford, W. F. Dryden, and P. A. Smith . 2003. Neurotrophic regulation of calcium channels by the peptide neurotransmitter luteinizing hormone releasing hormone. J Neurosci 23:7169–7175. Google Scholar

19.

S. Gillis and J. Watson . 1980. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med 152:1709–1719. Google Scholar

20.

A. Gobbetti and M. Zerani . 1992. Mammalian GnRH involvement in pros-taglandin F2 alpha and sex steroid hormones testicular release in two amphibian species: the anuran water frog, Rana esculenta, and the urodele crested newt, Triturus carnifex. Gen Comp Endocrinol 87:240–248. Google Scholar

21.

P. R. Gouldson, C. R. Snell, R. P. Bywater, C. Higgs, and C. A. Reynolds . 1998. Domain swapping in G-protein coupled receptor dimers. Protein Eng 11:1181–1193. Google Scholar

22.

C. Grundker, A. R. Gunthert, S. Westphalen, and G. Emons . 2002. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146:1–14. Google Scholar

23.

G. J. Hannon 2002. RNA interference. Nature 418:244–251. Google Scholar

24.

T. Iizumi, T. Yazaki, S. Kanoh, I. Kondo, and K. Koiso . 1987. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol 137:1304–1306. Google Scholar

25.

T. Ikemoto and M. K. Park . 2003. Identification and characterization of the reptilian GnRH-II gene in the leopard gecko, Eublepharis macularius, and its evolutionary considerations. Gene 316:157–165. Google Scholar

26.

T. Ikemoto, M. Enomoto, and M. K. Park . 2004. Identification and characterization of a reptilian GnRH receptor from the leopard gecko. Mol Cell Endocrinol 214:137–147. Google Scholar

27.

I. Ishiwata, C. Ishiwata, M. Soma, J. Arai, and H. Ishikawa . 1984. Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesterone receptors. Gynecologic Oncology 17:281–290. Google Scholar

28.

S. S. Kakar, L. C. Musgrove, D. C. Devor, J. C. Sellers, and J. D. Neill . 1992. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189:289–295. Google Scholar

29.

S. S. Kakar, S. Nath, J. Bunn, and L. Jennes . 1997. The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in alphaT3-1 cells by GnRH agonist. Anticancer Drugs 8:369–375. Google Scholar

30.

C. Klausen, J. P. Chang, and H. R. Habibi . 2002. Multiplicity of gonadotropin-releasing hormone signaling: a comparative perspective. Prog Brain Res 141:111–128. Google Scholar

31.

H. Kogo, A. Kudo, M. K. Park, T. Mori, and S. Kawashima . 1995. In situ detection of gonadotropin-releasing hormone (GnRH) receptor mRNA expression in the rat ovarian follicles. J Exp Zool 272:62–68. Google Scholar

32.

H. Kogo, T. Fujimoto, and T. Mori . 1999. Evidence for gonadotropin-releasing hormone receptor mRNA expression by estrogen in rat granulosa cells. Cell Tissue Res 297:459–465. Google Scholar

33.

H. Kogo, T. Fujimoto, M. K. Park, and T. Mori . 1999. Gonadotropin-releasing hormone receptor mRNA expression in the ovaries of neonatal and adult rats. Cells Tissues Organs 164:14–22. Google Scholar

34.

T. Kusakabe, S. Mishima, I. Shimada, Y. Kitajima, and M. Tsuda . 2003. Structure, expression, and cluster organization of genes encoding gonadotropin-releasing hormone receptors found in the neural complex of the ascidian Ciona intestinalis. Gene 322:77–84. Google Scholar

35.

N. Ling, S. Y. Ying, N. Ueno, S. Shimasaki, F. Esch, M. Hotta, and R. Guillemin . 1986. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 321:779–782. Google Scholar

36.

R. Maggio, P. Barbier, A. Colelli, F. Salvadori, G. Demontis, and G. U. Corsini . 1999. G protein-linked receptors: pharmacological evidence for the formation of heterodimers. J Pharmacol Exp Ther 291:251–257. Google Scholar

37.

B. Marchetti, V. Guarcello, M. C. Morale, G. Bartoloni, F. Raiti, G. Palumbo Jr, Z. Farinella, S. Cordaro, and U. Scapagnini . 1989. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology 125:1037–1045. Google Scholar

38.

L. S. Mathews 1994. Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310–325. Google Scholar

39.

H. Matsuo, Y. Baba, R. M. Nair, A. Arimura, and A. V. Schally . 1971. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43:1334–1339. Google Scholar

40.

D. D. Mickey, K. R. Stone, H. Wunderli, G. H. Mickey, R. T. Vollmer, and D. F. Paulson . 1977. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 37:4049–4058. Google Scholar

41.

L. E. Miles, A. C. Hanyaloglu, J. R. Dromey, K. D. Pfleger, and K. A. Eidne . 2004. Gonadotropin-releasing hormone receptor-mediated growth suppression of immortalized LbetaT2 gonadotrope and stable HEK293 cell lines. Endocrinology 145:194–204. Google Scholar

42.

R. Millar, S. Lowe, D. Conklin, A. Pawson, S. Maudsley, B. Troskie, T. Ott, M. Millar, G. Lincoln, R. Sellar, B. Faurholm, G. Scobie, R. Kuestner, E. Terasawa, and A. Katz . 2001. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98:9636–9641. Google Scholar

43.

R. P. Millar 2003. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 14:35–43. Google Scholar

44.

R. P. Millar, Z. L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley . 2004. Gonadotropin-releasing hormone receptors. Endocr Rev 25:235–275. Google Scholar

45.

G. Milligan, J. Lopez-Gimenez, S. Wilson, and J. J. Carrillo . 2004. Selectivity in the oligomerisation of G protein-coupled receptors. Semin Cell Dev Biol 15:263–268. Google Scholar

46.

K. Miyamoto, Y. Hasegawa, M. Nomura, M. Igarashi, K. Kangawa, and H. Matsuo . 1984. Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Proc Natl Acad Sci USA 81:3874–3878. Google Scholar

47.

K. Morgan, D. Conklin, A. J. Pawson, R. Sellar, T. R. Ott, and R. P. Millar . 2003. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144:423–436. Google Scholar

48.

J. D. Neill, L. W. Duck, J. C. Sellers, and L. C. Musgrove . 2001. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 282:1012–1018. Google Scholar

49.

J. D. Neill 2002. GnRH and GnRH receptor genes in the human genome. Endocrinology 143:737–743. Google Scholar

50.

Y. Oka 2002. Physiology and release activity of GnRH neurons. Prog Brain Res 141:259–281. Google Scholar

51.

M. K. Park, H. Kogo, H. Kaito, and T. Mori . 1999. Characterization of the GnRH receptor mRNA expression in the rat ovary. In “Recent Progress in Molecular and Comparative Endocrinology”. Ed by H. B. Kwon, J. M. P. Joss, and S. Ishii . Hormone Research Center, Chonnam National University. Kwangju. pp. 284–289. Google Scholar

52.

D. Pati and H. R. Habibi . 1995. Inhibition of human hepatocarcinoma cell proliferation by mammalian and fish gonadotropin-releasing hormones. Endocrinology 136:75–84. Google Scholar

53.

C. Peng and S. T. Mukai . 2000. Activins and their receptors in female reproduction. Biochem Cell Biol 78:261–279. Google Scholar

54.

K. D. Pfleger, K. M. Kroeger, and K. A. Eidne . 2004. Receptors for hypothalamic releasing hormones TRH and GnRH: oligomerization and interactions with intracellular proteins. Semin Cell Dev Biol 15:269–280. Google Scholar

55.

F. Raga, E. M. Casan, J. Kruessel, Y. Wen, F. Bonilla-Musoles, and M. L. Polan . 1999. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 140:3705–3712. Google Scholar

56.

T. W. Redding and A. V. Schally . 1983. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 80:1459–1462. Google Scholar

57.

T. Reissmann, A. V. Schally, P. Bouchard, H. Riethmiiller, and J. Engel . 2000. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 6:322–331. Google Scholar

58.

R. G. Romanelli, T. Barni, M. Maggi, M. Luconi, P. Failli, A. Pezzatini, E. Pelo, F. Torricelli, C. Crescioli, P. Ferruzzi, R. Salerno, M. Marini, C. M. Rotella, and G. B. Vannelli . 2004. Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. J Biol Chem 279:117–126. Google Scholar

59.

T. Sakai, K. Inoue, Y. Hasegawa, and K. Kurosumi . 1988. Effect of passive immunization to gonadotropin-releasing hormone (GnRH) using GnRH antiserum on the mitotic activity of gonadotrophs in castrated male rats. Endocrinology 122:2803–2808. Google Scholar

60.

A. V. Schally 1999. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20:1247–1262. Google Scholar

61.

P. B. Seshagiri, E. Terasawa, and J. P. Hearn . 1994. The secretion of gonadotrophin-releasing hormone by peri-implantation embryos of the rhesus monkey: comparison with the secretion of chorionic gonadotrophin. Hum Reprod 9:1300–1307. Google Scholar

62.

Y. Sharoni, E. Bosin, A. Miinster, J. Levy, and A. V. Schally . 1989. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86:1648–1651. Google Scholar

63.

Y. Shi 2003. Mammalian RNAi for the masses. Trends Genet 19:9–12. Google Scholar

64.

C. Sifer, G. Blanc-Layrac, A. F. Bringuier, R. Porcher, P. Madelenat, G. Feldmann, and J. L. Benifla . 2003. Effects of a Gonadotropin-Releasing Hormone agonist and Follicle Stimulating Hormone on the incidence of apoptosis in human luteinized granulosa cells. Eur J Obstet Gynecol Reprod Biol 110:43–48. Google Scholar

65.

K. R. Stone, D. D. Mickey, H. Wunderli, G. H. Mickey, and D. F. Paulson . 1978. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274–281. Google Scholar

66.

G. Storz 2002. An expanding universe of noncoding RNAs. Science 296:1260–1263. Google Scholar

67.

S. Takekida, H. Matsuo, and T. Maruo . 2003. GnRH agonist action on granulosa cells at varying follicular stages. Mol Cell Endocrinol 202:155–164. Google Scholar

68.

K. Terakado 2001. Induction of gamete release by gonadotropin-releasing hormone in a protochordate, Ciona intestinalis. Gen Comp Endocrinol 124:277–284. Google Scholar

69.

W. Vale, J. Rivier, J. Vaughan, R. McClintock, A. Corrigan, W. Woo, D. Karr, and J. Spiess . 1986. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321:776–779. Google Scholar

70.

W. van Biljon, S. Wykes, S. Scherer, S. A. Krawetz, and J. Hapgood . 2002. Type II gonadotropin-releasing hormone receptor transcripts in human sperm. Biol Reprod 67:1741–1749. Google Scholar
Masahiro Enomoto and Min Kyun Park "GnRH as a Cell Proliferation Regulator: Mechanism of Action and Evolutionary Implications," Zoological Science 21(10), 1005-1013, (1 October 2004). https://doi.org/10.2108/zsj.21.1005
Received: 28 July 2004; Published: 1 October 2004
KEYWORDS
cell proliferation
colony-formation
GnRH
GnRH receptor
reproduction
Back to Top